Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Puma Biotechnology Inc. Stock

Price
 
€6.81
-0.486
-6.660%
Target price
€5.00
10.12.19 / Frankfurt WKN: A1J643 / Name: Puma Biotechnology / Stock / Biotechnologie & medizinische Forschung
Latest predictions
€5.00
21.08.19
Your prediction

Puma Biotechnology Inc. Stock

Heavy losses for Puma Biotechnology Inc. today as the stock fell by -€0.486 (-6.660%).
With 1 Sell predictions and 0 Buy predictions the community sentiment towards the Puma Biotechnology Inc. stock is not clear.
A potential of -26.622%, resulting from comparing the current price of €6.81 with the target price of €5.00 for Puma Biotechnology Inc., shows the chance of incurring significant losses.
Register To Post

Other discussions about Puma Biotechnology Inc. Stock

Trading Puma Biotechnology Inc.

Trading Puma Biotechnology Inc.

New thread

News

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®

CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

Last name of Chief Executive Officer of Pierre Fabre Pharmaceuticals in fourth paragraph should read: Lowinski (instead of Lowinsky). The corrected release reads: PUMA BIOTECHNOLOGY AMENDS

Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer


Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in

Puma Biotechnology to Present at the Credit Suisse Healthcare Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Puma Biotechnology Reports Third Quarter 2019 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for